Mark D. Pegram
Impact in
- Oncology top 0.02%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Radiology, Nuclear Medicine and Imaging top 0.05%
- Monoclonal and Polyclonal Antibodies Research
Papers in
- Oncology 154
- HER2/EGFR in Cancer Research 115
- Cancer Treatment and Pharmacology 56
- Peptidase Inhibition and Analysis 11
-
- Monoclonal and Polyclonal Antibodies Research 64
- Radiopharmaceutical Chemistry and Applications 20
- Co-authors
- Dennis J. Slamon (34 shared papers)José Baselga (2 shared papers)W. Eiermann (9 shared papers)Brian Leyland‐Jones (2 shared papers)Alex Bajamonde (2 shared papers)Janet Wolter (1 shared paper)Larry Norton (1 shared paper)Steven Shak (1 shared paper)
- Journals
- Journal of Clinical Oncology (57 papers)Cancer Research (23 papers)Breast Cancer Research and Treatment (14 papers)Annals of Oncology (11 papers)Clinical Breast Cancer (10 papers)
- Partner nations
- United StatesGermanyUnited Kingdom
In The Last Decade
Mark D. Pegram
214 papers receiving 23.4k citations
Mark D. Pegram's Hit Papers
Peers
Comparison fields: 5 of 149
- Oncology 15.2k
- Radiology, Nuclear Medicine and Imaging 6.5k
- Cancer Research 3.8k
- Pulmonary and Respiratory Medicine 3.6k
- Genetics 1.1k
Countries citing papers authored by Mark D. Pegram
This map shows the geographic impact of Mark D. Pegram's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D. Pegram with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D. Pegram more than expected).
Fields of papers citing papers by Mark D. Pegram
This network shows the impact of papers produced by Mark D. Pegram. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D. Pegram. The network helps show where Mark D. Pegram may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark D. Pegram, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 222 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Hit paper breakdown → | 2001 | 8492 |
| 2 | Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer Hit paper breakdown → | 2012 | 2724 |
| 3 | Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. Hit paper breakdown → | 1998 | 848 |
| 4 | Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer Hit paper breakdown → | 2009 | 768 |
| 5 | Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells Hit paper breakdown → | 2006 | 714 |
| 6 | Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Hit paper breakdown → | 1999 | 540 |
| 7 | Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial Hit paper breakdown → | 2017 | 477 |
| 8 | 2003 | 454 | |
| 9 | 2004 | 395 | |
| 10 | Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. | 1994 | 362 |
| 11 | 1998 | 325 | |
| 12 | 1997 | 259 | |
| 13 | 2010 | 255 | |
| 14 | 2004 | 231 | |
| 15 | 1998 | 205 | |
| 16 | 2006 | 187 | |
| 17 | 2000 | 186 | |
| 18 | 2006 | 186 | |
| 19 | 2005 | 174 | |
| 20 | 2007 | 167 |
About Mark D. Pegram
Mark D. Pegram is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research, having authored 222 papers that have together received 24.0k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (115 papers), Monoclonal and Polyclonal Antibodies Research (64 papers), Cancer Treatment and Pharmacology (56 papers), Breast Cancer Treatment Studies (37 papers), Advanced Breast Cancer Therapies (32 papers), Radiopharmaceutical Chemistry and Applications (20 papers), Glycosylation and Glycoproteins Research (14 papers) and Peptidase Inhibition and Analysis (11 papers). The work is most often cited by research in Oncology (15.2k citations), Radiology, Nuclear Medicine and Imaging (6.5k citations), Cancer Research (3.8k citations), Pulmonary and Respiratory Medicine (3.6k citations) and Genetics (1.1k citations). Mark D. Pegram has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Dennis J. Slamon, José Baselga, W. Eiermann, Brian Leyland‐Jones, Alex Bajamonde, Janet Wolter, Larry Norton, Steven Shak, Virginia Paton and Thomas Fleming. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Breast Cancer Research and Treatment, Annals of Oncology and Clinical Breast Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.